Skip to main content

Gevotroline

Multi tool use
Multi tool use









Gevotroline


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search

























































Gevotroline
Gevotroline.svg
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status

  • In general: uncontrolled


Identifiers
CAS Number
  • 107266-06-8

PubChem CID
  • 60547
ChemSpider
  • 54579
UNII
  • 7SZ6A2091Q
ChEBI
  • CHEBI:142391
Chemical and physical data
Formula
C19H20FN3
Molar mass 309.38 g/mol
3D model (JSmol)
  • Interactive image

Gevotroline (WY-47,384) is an atypical antipsychotic with a tricyclic structure which was under development for the treatment of schizophrenia by Wyeth-Ayerst.[1][2][3] It acts as a balanced, modest affinity D2 and 5-HT2 receptor antagonist and also possesses high affinity for the sigma receptor.[2][4][5][6] It was well-tolerated and showed efficacy in phase II clinical trials but was never marketed.[2][3]



See also[edit]



  • Atypical antipsychotic

  • Atiprosin

  • Azepindole



References[edit]





  1. ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ abc Bristol, James A. (1990). Annual Reports in Medicinal Chemistry (Volume 25). Boston: Academic Press. ISBN 0-12-040525-3.


  3. ^ ab Stone, T. W.; Stone, Trevor (1996). CNS neurotransmitters and neuromodulators: dopamine. Boca Raton: CRC Press. ISBN 0-8493-7632-7.


  4. ^ Snyder SH, Largent BL (1989). "Receptor mechanisms in antipsychotic drug action: focus on sigma receptors". The Journal of Neuropsychiatry and Clinical Neurosciences. 1 (1): 7–15. PMID 2577720.


  5. ^ Matheson GK, Guthrie D, Bauer C, Knowles A, White G, Ruston C (January 1991). "Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat". Neuropharmacology. 30 (1): 79–87. doi:10.1016/0028-3908(91)90046-E. PMID 1675451.


  6. ^ Gudelsky GA, Nash JF (February 1992). "Neuroendocrinological and neurochemical effects of sigma ligands". Neuropharmacology. 31 (2): 157–62. doi:10.1016/0028-3908(92)90026-L. PMID 1348112.














Retrieved from "https://en.wikipedia.org/w/index.php?title=Gevotroline&oldid=862767628"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.020","walltime":"1.201","ppvisitednodes":{"value":4746,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":435836,"limit":2097152},"templateargumentsize":{"value":110427,"limit":2097152},"expansiondepth":{"value":14,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":17965,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 677.518 1 -total"," 56.49% 382.750 1 Template:Drugbox"," 36.66% 248.397 1 Template:Infobox"," 30.57% 207.112 23 Template:Navbox"," 19.58% 132.691 1 Template:Reflist"," 18.75% 127.049 1 Template:Navboxes"," 11.41% 77.322 16 Template:Unbulleted_list"," 11.39% 77.185 3 Template:Cite_book"," 9.93% 67.271 1 Template:Serotonin_receptor_modulators"," 5.45% 36.916 3 Template:Cite_journal"]},"scribunto":{"limitreport-timeusage":{"value":"0.295","limit":"10.000"},"limitreport-memusage":{"value":4916186,"limit":52428800}},"cachereport":{"origin":"mw1240","timestamp":"20181216022722","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":101,"wgHostname":"mw1266"});});WvyA z f,2qQ6
2G9O83A,YGRT3uEDDWE2o5k,K1avq4JkN3S PO5ke6517dI3v ExJRxCXtA4n4fguBL,XP yw4VCv

Popular posts from this blog

Full-time equivalent

Haven (TV series)

さくらももこ